Target intelligence / Profile preview

Glutamate receptor ionotropic AMPA subunit 3 (GluA3)

Target
GluA3
Molecular classification
Receptor, Ion channel, Ligand-gated ion channel, Ionotropic glutamate receptor, AMPA-type glutamate receptor
01

Overview

Glutamate receptor ionotropic AMPA subunit 3 (GluA3), encoded by the GRIA3 gene, is one of the four main subunits (GluA1–4) of AMPA-type ionotropic glutamate receptors, which are key mediators of rapid excitatory neurotransmission in the central nervous system[1][3]. GluA3 is a tetrameric cation channel permeable to Na+ and sometimes Ca2+, assembled together with other subunits to form functional receptors[3]. Unique among AMPARs, the GluA3 protein has a special structure—its extracellular domains (NTD and LBD) are closely coupled across all gating states, a feature that impacts receptor signaling, trafficking, and is associated with human neurological disease[2][4]. GluA3-containing receptors regulate synaptic strength and plasticity, playing a crucial role in learning and memory[6][1]. Dysfunction or mutation in GluA3 has been linked to epilepsy, neurodegenerative disorders, and mood disturbances[4][1]. Pharmacological antagonists of AMPARs that include GluA3 are used to treat epilepsy and are under investigation for other CNS diseases[5].

Other names
Glutamate receptor 3GRIA3 (gene symbol)GluR3AMPA receptor subunit GluA3
02

Mechanism of action

Non-competitive antagonism of the ion channel (e.g., perampanel); Competitive antagonism at the glutamate binding site (e.g., NBQX); Allosteric modulation of synaptic plasticity and conductance states

03

Biological functions

Excitatory neurotransmissionSynaptic plasticitySignal transductionFast depolarization of postsynaptic neuronsRegulation of Ca2+ and Na+ flow into neurons
04

Disease associations

Neurodegenerative diseaseEpilepsyDementiaMood disordersOther neurological disorders
05

Safety considerations

Impairment of normal excitatory neurotransmission (may cause cognitive/memory dysfunction)Possible psychiatric and mood effects (since GluA3 is implicated in mood disorders)Disruption of synaptic plasticityExcitotoxicity risk if improperly modulated
06

Interacting drugs

Perampanel

4 more in the full profile.

07

Biomarkers

GluA3 expression and isoform presence in brain regions could serve as biomarkers for neurological disease susceptibility or progression (currently mainly research-oriented)Autoantibodies against GluA3 have been associated with some autoimmune encephalitis cases (rare, research stage)

Beyond the preview

Go deeper on Glutamate receptor ionotropic AMPA subunit 3 (GluA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic AMPA subunit 3 (GluA3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call